Epitome Pharmaceuticals identifies, develops and licenses promising medications. Investigation is conducted by reading the scientific literature, discussing anomalies and questions with leaders in their fields, and by statistical reanalysis of published data.

Once a remedy has been identified and intellectual property rights secured, we proceed to advance the development of the medication. We clarify regulatory issues through close cooperation with regulatory agencies. Based on our research and the prospects for a specific medication, we may file an IND and initiate Phase I or Phase II trials.

Ultimately, Epitome Pharmaceuticals seeks to license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.

Polyphenon® E for The Treatment of
HPV Infections

In 1997 Epitome Pharmaceuticals Ltd. licensed from Mitsui Norin Company (Japan), a patented method of treating external genital warts through the topical application of Polyphenon® E green tea extract. 

Read More...

Twin Sample™ Biopsy Needle (Now available)

The Twin Sample biopsy needle was invented to address the need for fresh tissue for molecular assays. The needle harvests paired samples with minimal intrusion, one for the pathology and the other for your lab. ​

READ MORE...

Topical Therapy for the Treatment of
Chronic Pain

In 1999 Epitome Pharmaceuticals Ltd. licensed from Dalhousie University (Canada) a patented method for treating neuropathic pain through the topical application of a formulation containing ketamine and amitriptylline. 

Read More...

Cold Sore Prevention

On October 26, 2011 the US patent office allowed the Epitome Pharmaceuticals patent for a lip balm formulation containing 1% Vitamin C and 2% green tea extract, as well as an enhancer for absorption. ​

Read More...


Early Drug Development in Cooperation with the Pharmaceutical Industry


Epitome Pharmaceuticals identifies, develops and licenses promising medications and technologies. Investigation is conducted by reading the scientific literature, discussing anomalies and questions with leaders in their fields, and by statistical reanalysis of published data. Once a remedy has been identified and intellectual property rights secured, we proceed to advance the development of the medication. We clarify regulatory issues through close cooperation with regulatory agencies. Based on our research and the prospects for a specific medication, we may file an IND and initiate Phase I or Phase II trials.

Ultimately, Epitome Pharmaceuticals seeks to license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.